Catalyst
Slingshot members are tracking this event:
Target enrollment of 500 patients in AR101 PALISADE Phase 2 studies is on track to complete in the second half of this year, and we expect top-line data in the second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AIMT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Palisade, Peanut-allergic Individuals
